XSHE
002603
Market cap4.27bUSD
Feb 24, Last price
17.57CNY
1Q
-8.35%
Jan 2017
42.73%
IPO
35.47%
Name
Shijiazhuang Yiling Pharmaceutical Co Ltd
Chart & Performance
P/E
—
P/S
4.51
EPS
—
Div Yield, %
1.71%
Shrs. gr., 5y
—
Rev. gr., 5y
2.26%
Revenues
6.51b
-36.88%
Net income
-725m
L
CFO
611m
+293.04%
Dividend
Oct 22, 20250.3 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of medicine primarily in China. The company operates through Chemical and Biological Medicine, and Health Industry segments. It offers drugs for cardiac and premature ventricular beats, sinus bradycardia, chronic heart failure, integrated rhythm regulation, cold and respiratory, cardiovascular and cerebrovascular diseases, diabetes field, tumor medication, and others. The company sells its products through physical display and online. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||